KNB Stock Overview
A digital health company, engages in the research, development and commercialization of cannabis-derived formulations and therapeutic inhalation devices.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Kanabo Group Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.015 |
| 52 Week High | UK£0.032 |
| 52 Week Low | UK£0.011 |
| Beta | 3.1 |
| 1 Month Change | -14.71% |
| 3 Month Change | -23.68% |
| 1 Year Change | -35.56% |
| 3 Year Change | -92.56% |
| 5 Year Change | n/a |
| Change since IPO | -96.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| KNB | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -14.7% | -0.6% | -1.5% |
| 1Y | -35.6% | 8.7% | 3.8% |
Return vs Industry: KNB underperformed the UK Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: KNB underperformed the UK Market which returned 3.8% over the past year.
Price Volatility
| KNB volatility | |
|---|---|
| KNB Average Weekly Movement | 10.0% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.8% |
Stable Share Price: KNB's share price has been volatile over the past 3 months.
Volatility Over Time: KNB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 20 | Avihu Tamir | www.kanabogroup.com |
Kanabo Group Plc, a digital health company, engages in the research, development and commercialization of cannabis-derived formulations and therapeutic inhalation devices. It operates through Primary Care and Secondary Care segments. The company offers The GP Service, an online telehealth platform, that provides patients with video consultations, online prescriptions, and primary care services; and operates Treat It, an online clinic focused on management of chronic pain.
Kanabo Group Plc Fundamentals Summary
| KNB fundamental statistics | |
|---|---|
| Market cap | UK£9.17m |
| Earnings (TTM) | -UK£7.99m |
| Revenue (TTM) | UK£895.00k |
10.2x
P/S Ratio-1.1x
P/E RatioIs KNB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNB income statement (TTM) | |
|---|---|
| Revenue | UK£895.00k |
| Cost of Revenue | UK£761.00k |
| Gross Profit | UK£134.00k |
| Other Expenses | UK£8.12m |
| Earnings | -UK£7.99m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 14.97% |
| Net Profit Margin | -892.40% |
| Debt/Equity Ratio | 3.6% |
How did KNB perform over the long term?
See historical performance and comparison